MAMaria Camila Suarez Arbelaez

Maria Camila Suarez Arbelaez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Camila Suarez Arbelaez has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of testicular volume discrepancy and total testicular volume as predictors of semen parameters in adolescents with unilateral left varicocele

    by Adele Raymo, Maria Camila Suarez, Maxwell Towe, Cody B. Jackson, Luciana Lerendegui, Daniel E. Nassau, Rafael Gosalbez, Miguel Castellan, Andrew Labbie, Alireza Alam


  • Thulium Fiber Laser-Assisted En-Bloc Resection and Ablation of Renal Pelvis Tumors in a High-Risk Post-Cystectomy Patient: A Technique Guide for Novice Endourologist

    by Maria C. Suarez, Aravindh Rathinam, Archan Khandekar, Jonathan Katz, Robert Marcovich, Hemendra Shah

    Introduction and Objectives: Upper tract urothelial cancer (UTUC) occurs in 0.75%−6.4% of patients after radical cystectomy for bladder cancer. Radical nephroureterectomy (NUT) is the gold standard for high-grade, organ-confined UTUC; however, minimally invasive alternatives are considered for high-risk patients. While en bloc resection of bladder tumors has gained attention, there is no report of en bloc resection for UTUC. We present a technique using thulium-fiber laser en bloc resection of a renal pelvis tumor in a high-risk patient with an ileal conduit. Methods: An 81-year-old underwent robotic-assisted radical cystectomy with ileal conduit diversion 6 years ago (Bricker anastomosis). During surveillance, a computed-tomography-urography revealed nodularity in the renal pelvis and proximal left ureter, suggestive of UTUC. The patient had multiple comorbidities, with a Charlson-Comorbidity-Index of 10 points. She declined NUT and opted for endoscopic resection. Ureteroscopy through the ileal conduit revealed multiple papillary tumors at the ureteropelvic junction, posterior renal pelvis, and lower-pole calyx. Using a 200-micron thulium fiber laser (1 J × 10 Hz), en bloc resection was performed. The video demonstrates our surgical technique in detail. Results: Complete resection of the tumors was achieved in a bloodless manner. The patient had no intra- or perioperative complications and was discharged the same day. At the 2-week follow-up, she remained asymptomatic and successfully removed her stent. Pathology confirmed noninvasive high-grade papillary UTUC. She is scheduled for multidisciplinary management with a medical oncologist. Her follow-up ureteroscopy at 3 months revealed no tumor recurrence. Conclusion: Thulium fiber laser assisted en-bloc resection is a safe, feasible approach for endoscopic management of UTUC. Music: Soundtrack from Canva Popular Music Library ( https://www.canva.com/policies/popular-music-license/ ). Patient Consent Statement: Author(s) have received and archived patient consent for video recording/publication in advance of video recording of the procedure. The authors have no conflicts of interest to disclose related to the publication of this work. The authors received no external funding for this work. Runtime of video: 4 mins and 50 secs.

  • Open Access

    Transurethral resection of the prostate across continents: a meta-analysis evaluating quality of gold standard in the twenty-first century

    by Joao G. Porto, Ansh M. Bhatia, Abhishek Bhat, Maria Camila Suarez Arbelaez, Ruben Blachman-Braun, Khushi Shah, Ankur Malpani, Diana Lopategui, Thomas R. W. Herrmann, Robert Marcovich, et al.

    Purpose: To compare outcomes of transurethral resection of the prostate (TURP) across different regions worldwide over the past two decades. Methods: A systematic review and meta-analysis of randomized clinical trials indexed to PubMed that assessed TURP. A total of 102 studies with 8,454 patients were included and grouped by continents: Europe, Asia, Africa, and Others (North America, South America, and Australia). International Prostate Symptom Score (IPSS), peak flow (Qmax), postvoid residual urine (PVR), PSA levels, prostate volume, and Sexual Health Inventory for Men scores (at 3, 12, and 36 months) were assessed, along with postoperative complications. Heterogeneity across studies was classified as low (I 2 < 25%), moderate (I 2 = 25–75%), or high (I 2 > 75%). Results: TURP consistently exhibited significant enhancements in IPSS, Qmax, and PVR across various regions. Notably, PVR demonstrated high heterogeneity (I²=100%). TURP presented low complication rates with TURP syndrome (2%), bleeding (8%), and blood transfusion (6%). However, significant heterogeneity was observed, particularly for clot evacuation (I 2 = 87%), irritative symptoms (I 2 = 96%), and incontinence (I 2 = 84%). The retreatment rates at 1 and 3 years were 5% and 7%, respectively, with significant differences across regions. Conclusion: Global outcomes of TURP lack a discernible trend. The substantial heterogeneity observed among continents suggests a lack of standardization. Nevertheless, uniform symptomatic improvements among patients still support TURP as the gold-standard surgical treatment for benign prostatic hyperplasia, despite variations in its results worldwide.


  • Open Access

    Evaluating transurethral resection of the prostate over twenty years: a systematic review and meta-analysis of randomized clinical trials

    by Joao G. Porto, Ansh M. Bhatia, Abhishek Bhat, Maria Camila Suarez Arbelaez, Ruben Blachman-Braun, Khushi Shah, Ankur Malpani, Diana Lopategui, Thomas R. W. Herrmann, Robert Marcovich, et al.

    Purpose: The goal of this systematic review is to assess the temporal changes in outcomes and complications of transurethral resection of the prostate (TURP) from 2000 to 2022. Methods: We conducted a systematic review and meta-analysis of 103 randomized clinical trials from PubMed on TURP, involving 8521 patients. Studies were grouped by years: 2000–2004, 2005–2009, 2010–2014, and 2015–2022. We assessed International Prostate Symptom Score (IPSS), Peak Flow (Qmax), Post-void residue of urine (PVR), and post-operative complications. Heterogeneity was ranked as low (I2 < 25%), moderate (I2 = 25–75%), or high (I2 > 75%). Results: TURP significantly improved IPSS, Qmax, and PVR, with the most recent studies showing superior results in IPSS and Qmax after 3 years compared to 2000–2004 studies. Heterogeneity in PVR was high (I2 = 100%). No negative impact on erectile function was observed. Complication rates included TURP syndrome (2%), bleeding (8%), and blood transfusion (6%), but elevated heterogeneity with difference between the groups was seen in clot evacuation (I2 = 83%) and urinary tract infections (I2 = 82%). Other complications were urinary retention (4%), incontinence (8%), urethral stricture (3%), bladder neck stenosis (2%). Conclusion: In the last 20 years there has not been a clear trend in the results of TURP. The found heterogeneity may indicate a lack of standardization in TURP procedures. However, symptomatic improvement among patients is uniform, which supports this procedure as a historical benchmark surgical treatment for BPH.


  • Geographical Distribution of International Medical Graduates Across US Urology Residency Programs: An Analysis of Trends and Outcomes

    by Braian R. Ledesma, Manish Narasimman, Maria Camila Suarez Arbelaez, Joshua White, Ari P. Bernstein, Justin Loloi, Ranjith Ramasamy


  • Open Access

    The Influence of the Microbiome on Urological Malignancies: A Systematic Review

    by Joao G. Porto, Maria Camila Suarez Arbelaez, Brandon Pena, Archan Khandekar, Ankur Malpani, Bruno Nahar, Sanoj Punnen, Chad R. Ritch, Mark L. Gonzalgo, Dipen J. Parekh, et al.

    The microbiome, once considered peripheral, is emerging as a relevant player in the intricate web of factors contributing to cancer development and progression. These often overlooked microorganisms, in the context of urological malignancies, have been investigated primarily focusing on the gut microbiome, while exploration of urogenital microorganisms remains limited. Considering this, our systematic review delves into the complex role of these understudied actors in various neoplastic conditions, including prostate, bladder, kidney, penile, and testicular cancers. Our analysis found a total of 37 studies (prostate cancer 12, bladder cancer 20, kidney cancer 4, penile/testicular cancer 1), revealing distinct associations specific to each condition and hinting at potential therapeutic avenues and future biomarker discoveries. It becomes evident that further research is imperative to unravel the complexities of this domain and provide a more comprehensive understanding.


  • Does preoperative screening VCUG affect the outcomes and complications of pyeloplasty in patients with ureteropelvic junction obstruction?

    by Maria Camila Suarez Arbelaez, Kashish Khanna, Adele Raymo, Alexander Weber, Luciana Lerendegui, Sirpi Nackeeran, Rafael Gosalbez, Andrew S. Labbie, Miguel A. Castellan, Daniel E. Nassau, et al.


  • Open Access

    The Influence of Microbiome on Urological Malignancies: A Systematic Review

    by Joao G. Porto, Maria Camila Suarez, Brandon Peña, Archan Khandekar, Ankur Malpani, Bruno Nahar, Sanoj Punnen, Chad R. Ritch, Mark L. Gonzalgo, Dipen J. Parekh, et al.

    The microbiome, once considered peripheral, is emerging as a relevant player in the intricate web of factors contributing to cancer development and progression. These often overlooked microorganisms, in the context of urological malignancies, have been investigated primarily focusing on the gut microbiome, while exploration of urogenital microorganisms remains limited. In light of this, our systematic review delves into the complex role of these understudied actors in various neoplastic conditions, including prostate, bladder, kidney, penile, and testicular cancers. Our analysis found a total of 37 studies, with prostate cancer-12, bladder cancer-20, kidney cancer-4, penile/testicular cancer-1, which reveals distinct associations specific to each condition, hinting at potential therapeutic avenues and future biomarker discoveries. It becomes evident that further research is imperative to unravel the complexities of this domain and provide a more comprehensive understanding.


  • Next-generation sequencing analysis of semen microbiome taxonomy in men with nonobstructive azoospermia vs. fertile controls: a pilot study

    by Katherine Campbell, Maria Camila Suarez Arbelaez, Armin Ghomeshi, Emad Ibrahim, Sabita Roy, Praveen Singh, Kajal Khodamoradi, Aaron Miller, Scott D. Lundy, Ranjith Ramasamy


  • Complications associated with minimally invasive surgical therapies (MIST) for surgical management of benign prostatic hyperplasia: a Manufacturer and User Facility Device Experience (MAUDE) database review

    by Joao G. Porto, Maria Camila Suarez Arbelaez, Ruben Blachman-Braun, Ansh Bhatia, Shivank Bhatia, Ramgopal Satyanarayana, Robert Marcovich, Hemendra N. Shah

    Purpose MAUDE database houses medical device reports of suspected device-related complications received by Food and Drug Administration. In the present study we aim to evaluate the MAUDE database for reported complications of MIST procedures. Methods The database was queried using keywords: rezum, urolift, prostate embolization (PAE), transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), prostate stent and Temporarily Implanted Nitinol Device (iTIND) on 10/1/22 to extract information regarding device problems and procedure-related complications. Gupta classification system was used to stratify complications. Statistical analysis was performed to compare frequency of complications among MIST procedures. Results We found a total of 692 reports (Rezum-358, urolift-226, PAE-53, TUNA-31, TUMT-19, prostatic stent-4, and iTIND-1). Most complications related to device or users were minor (level 1 and 2) and there was no significant difference among various MIST procedures. The screen/system error was responsible for 93% and 83% aborted cases in Rezum and TUNA, respectively, and PAE showed 40% of device component detachment/fracture. Overall Urolift and TUMT were associated with statistically significant higher incidence of major (level 3 and 4) complications (23% and 21%, respectively) as compared with Rezum (7%). Most major complications needing hospitalization after Urolift included hematoma and hematuria with clots and those after Rezum included urinary tract infection and sepsis. Thirteen deaths were reported, mostly due to cardiovascular events, which were classified as not associated with the proposed treatment. Conclusion MIST for BPH can occasionally cause significant morbidity. Our data should assist urologists and patients in shared decision-making process.